Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer
An Assessment of the Biological and Clinical Effects of Palbociclib (PD 0332991) With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Patients With Premenopausal Estrogen-Receptor Positive/HER2-Negative Primary Breast Cancer
Sponsor: Genomic Health®, Inc.
A PHASE2 clinical study on Breast Cancer, this trial is completed. The trial is conducted by Genomic Health®, Inc. and has accumulated 14 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
May 2022 — Jul 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
May 2021 — May 2022 [monthly]
Active Not Recruiting PHASE2
▶ Show 9 earlier versions
-
Jan 2021 — May 2021 [monthly]
Active Not Recruiting PHASE2
-
Oct 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Dec 2019 — Oct 2020 [monthly]
Recruiting PHASE2
-
Sep 2019 — Dec 2019 [monthly]
Recruiting PHASE2
-
Jul 2019 — Sep 2019 [monthly]
Recruiting PHASE2
-
Jun 2019 — Jul 2019 [monthly]
Recruiting PHASE2
-
Apr 2019 — Jun 2019 [monthly]
Recruiting PHASE2
-
Feb 2019 — Apr 2019 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Sep 2018 — Feb 2019 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Genomic Health®, Inc.
- NSABP Foundation Inc
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .